Phase 1 Pharmacokinetics and Safety Study of Oral Soticlestat in Participants With Moderate or Mild Hepatic Impairment and Normal Hepatic Function
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Soticlestat (Primary)
- Indications Complex regional pain syndromes; Dravet syndrome; Epilepsy; Lennox-Gastaut syndrome; Liver failure; Myoclonic epilepsies; Tuberous sclerosis
- Focus Pharmacokinetics
- Sponsors Takeda
- 16 Jun 2022 Status changed from recruiting to completed.
- 20 May 2022 Planned End Date changed from 19 Oct 2022 to 10 Jun 2022.
- 20 May 2022 Planned primary completion date changed from 10 Jun 2022 to 1 Jun 2022.